Arrowhead Pharmaceuticals, Inc. (ARWR)

$20.47

-0.71

(-3.35%)▲

Live

Performance

  • $19.83
    $21.14
    $20.47
    downward going graph

    3.13%

    Downside

    Day's Volatility :6.2%

    Upside

    3.17%

    downward going graph
  • $17.05
    $39.83
    $20.47
    downward going graph

    16.71%

    Downside

    52 Weeks Volatility :57.19%

    Upside

    48.61%

    downward going graph

Returns

PeriodArrowhead Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-26.33%
3.6%
0.0%
6 Months
-11.45%
10.2%
0.0%
1 Year
-14.22%
19.6%
0.0%
3 Years
-68.34%
16.8%
-23.0%

Highlights

Market Capitalization
2.6B
Book Value
$2.66
Earnings Per Share (EPS)
-4.65
PEG Ratio
-1.32
Wall Street Target Price
47.29
Profit Margin
0.0%
Operating Margin TTM
-2785.05%
Return On Assets TTM
-40.72%
Return On Equity TTM
-151.84%
Revenue TTM
19.6M
Revenue Per Share TTM
0.17
Quarterly Revenue Growth YOY
-94.3%
Gross Profit TTM
240.7M
EBITDA
-529.8M
Diluted Eps TTM
-4.65
Quarterly Earnings Growth YOY
0.1
EPS Estimate Current Year
-4.74
EPS Estimate Next Year
-4.22
EPS Estimate Current Quarter
-0.55
EPS Estimate Next Quarter
-0.63

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Arrowhead Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 131.02%

Current $20.47
Target $47.29

Technicals Summary

Sell

Neutral

Buy

Arrowhead Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
5.9%
-11.45%
-14.22%
-68.34%
-41.97%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
NA
NA
-1.32
-4.74
-1.52
-0.41
NA
2.66
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Buy
$2.6B
-41.97%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Arrowhead Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 16.09M → 3.55M (in $), with an average decrease of 77.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -125.3M → -170.79M (in $), with an average decrease of 36.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 99.6%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 113.1%

Institutional Holdings

  • BlackRock Inc

    12.62%

  • Vanguard Group Inc

    9.83%

  • venBio Select Advisor LLC

    7.15%

  • FMR Inc

    5.48%

  • State Street Corp

    4.70%

  • Slate Path Capital LP

    3.33%

Corporate Announcements

  • Arrowhead Pharmaceuticals, Inc. Earnings

    Arrowhead Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing

Organization
Arrowhead Pharmaceuticals, Inc.
Employees
525
CEO
Dr. Christopher R. Anzalone Ph.D.
Industry
Health Technology

Discover More

FAQs